Startups · AI

Senior Director, Translational Medicine and Clinical Biomarkers

Nurix AI · Brisbane, California · On-site

← All jobs
About Nurix AI

AI agents that run your enterprise workflows and get measurably better over time. 150+ enterprises live in production across retail, insurance, and financial services. Backed by Accel and General Catalyst.

About the role

The posted range applies to roles based in the San Francisco Bay Area and reflects local market conditions. Where an offer lands within that range depends on the candidate’s relevant experience, technical expertise, and how their background aligns with the role’s requirements.

What they're looking for

  • Set the strategic direction for evaluation and adoption of novel biomarker technologies and platforms, positioning Nurix's biomarker capabilities ahead of program needs rather than reacting to them
  • Provide senior scientific and strategic input into clinical trial design across programs, influencing go/no-go and dose-selection decisions where biomarker data is a critical input
  • Directly manage and develop at least one direct report, with responsibility for hiring and scaling the team as pipeline needs grow
  • Act as a key scientific stakeholder in due diligence, business development, and external partnership discussions where biomarker strategy or capabilities are relevant
  • Model strong executive presence and sound judgment under ambiguity, translating complex biomarker science for scientific and non-scientific audiences alike, including executive leadership and the Board
More about this role

Senior Director, Translational Medicine and Clinical Biomarkers

Own the translational science that decides which patients get treated and how — leading biomarker strategy across Nurix’s entire oncology and immunology portfolio. This is a senior, portfolio-level role with direct influence on trial design, dosing decisions, and executive strategy from day one.

  • Own and evolve the clinical biomarker strategy across Nurix's full clinical portfolio, setting priorities that inform patient stratification, response prediction, and resistance mechanisms for multiple concurrent programs (not a single franchise or indication).
  • Provide scientific interpretation of biomarker data, informed by a strong understanding of cell and tumor biology, molecular biology, inflammation, and immuno-oncology, helping translate those insights into patient-selection, dose-selection, go/no-go, and program-level development decisions.
  • Direct the build-out and governance of biomarker assay capabilities across the portfolio, including assay qualification standards, platform strategy, and vendor/CRO oversight, to ensure consistent, scalable execution across programs rather than one-off, program-specific...

Read the full posting on Nurix AI's site ↗

Translational

Build your edge while you search

Free tools for founders and investors, plus VC Unfiltered, our take on startups, venture and the people who build them.